News



18/Sep/2020

BOSTON–(BUSINESS WIRE)–The recent licensing deal between Mercury Therapeutics and Debiopharm showcases the highly successful partnership between Mercury Therapeutics and CreaGen Biosciences, said CreaGen in a statement released today.

For the past three years, Mercury has partnered with CreaGen for medicinal chemistry-based outsourcing of their lead generation program seeking to develop small molecule activators of AMP activated protein kinase. Novel AMPK activators hold promise for the treatment of type 2 diabetes, cardiovascular disease, and cancer.

more…




Subscribe


Sign up for CreaGen Inc newsletter to receive all the news.




Social networks



Twitter

#WeCare




Contact us




Send us an email

rrajur@creageninc.com



Subscribe


Sign up for Medicare newsletter to receive all the news offers and discounts from Medicare eye clinic.




Social networks



Twitter

#WeCare





© CreaGen Inc 2019. All rights reserved. Designed by Inqude



© CreaGen Inc 2019. All rights reserved. Designed by Inqude